Overview
Q-Centrix provides Enterprise Clinical Data Management (eCDM) that combines software with a large team of clinical data experts to turn unstructured clinical data into structured insights for hospitals, health systems, and life sciences. It abstracts, curates, and analyzes data across specialties like oncology, cardiovascular care, and trauma to support quality measurement, regulatory reporting, and operational improvement. The company differentiates itself by blending technology with a substantial clinical data workforce and targeted registries, enabling easier participation in clinical research and CMS reporting; acquisitions like CHAMPS Oncology and its later integration with MRO Corp expand oncology data capabilities and data exchange. Its goal is to improve healthcare performance and patient outcomes by delivering high-quality data and analytics that support value-based care and research collaborations.
Work here?Claim your company
Simplify's take
What believers are saying
- MRO launched Prodigy on September 23, 2026 for NCDR and STS registries.
- The June 2025 acquisition gives Q-Centrix broader cross-sell access across 7,000 clinics.
- The May 7, 2026 pediatric case study shows stronger shared-savings and quality performance.
What critics are saying
- Hospitals can replace manual abstraction with EMR-native analytics, crushing Q-Centrix renewals by 2027.
- MRO's 2026 acquisitions create integration drag, distracting teams and delaying product cohesion.
- A security incident tied to MRO in February 2026 damages trust with health systems.
What makes Q-Centrix unique
- MRO folded Q-Centrix into a 2,500-hospital, 35,000-clinic clinical data platform.
- Q-Centrix combines abstraction experts with software for registry, quality, and research workflows.
- Prodigy and Vyne Medical extend coverage from document intake through registry abstraction.
Help us improve and share your feedback! Did you find this helpful?